[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.249.135. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1994

Persistent and Recurrent Neovascularization After Laser Photocoagulation for Subfoveal Choroidal Neovascularization of Age-Related Macular Degeneration

Author Affiliations

Prepared for the Macular Photocoagulation Study (MPS) Group by Maureen G. Maguire, PhD; Michael L. Klein, MD; R. Joseph Olk, MD; Deborah A. Phillips; Judith Alexander; Noreen B. Javornik, MS; Cheryl Hiner; Marta J. Marsh, MS; Neil M. Bressler, MD; Lawrence J. Singerman, MD; Jim Matheny; and Jayne Brown. A complete list of the participants of the MPS Group as of March 31, 1993, appears on page 482 of this issue of the Archives. No member of the MPS Group has any proprietary interest in the development or marketing of any commercially available products used by these studies.

Arch Ophthalmol. 1994;112(4):489-499. doi:10.1001/archopht.1994.01090160065024
Abstract

Objective:  To determine the incidence and visual impact of and risk factors for persistent and recurrent neovascularization after laser photocoagulation of subfoveal choroidal neovascularization (CNV) in patients with age-related macular degeneration.

Design, Patients, and Methods:  The records of 189 eyes in the Subfoveal New CNV Study and 100 eyes in the Subfoveal Recurrent CNV Study assigned to laser photocoagulation were examined. Persistent CNV (detected within 6 weeks of treatment) and recurrent CNV (detected after 6 weeks) were defined angiographically by fluorescein leak-age from the periphery of the treatment scar. Incidence was estimated using survival analysis methods.

Results:  In both studies, persistent CNV was observed in approximately 13% of the eyes, and recurrent CNV was estimated to have developed by 3 years in an additional 35% of the eyes. In the New CNV Study, by 3 years, 36% of the eyes with persistent CNV had lost 6 or more lines of visual acuity as had 19% of the eyes with recurrent CNV and 27% of the eyes without persistence or recurrence. The presence of neovascular maculopathy in the fellow eye was associated with an increased risk for persistence or recurrence in the study eye. In the New CNV Study, partial coverage of the lesion with heavy laser treatment and/or runoff was associated with increased risk for persistence; less extensive natural scarring of the lesion at study entry was associated with increased risk for recurrence.

Conclusions:  Close to half of the eyes treated for sub foveal CNV have persistent or recurrent CNV within 3 years. There is a strong association between neovascular maculopathy in the fellow eye and the inability of laser photocoagulation to permanently obliterate signs of CNV from the study eye. Within these two studies, there was little additional damage to visual function resulting from persistent or recurrent neovascularization. There appears to be no reason to deviate from the protocol goal of covering the entire neovascular complex when treating eyes with subfoveal CNV.

×